Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | TERT | O14746 | 1/20 | 0.32 |
| ▸ | KCNK2 | O95069 | 2/20 | 0.31 |
| ▸ | KCNK10 | P57789 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13036717 | 0.84 | CA2 (0.39) | CA2CA1CA5ACA9TERT | |
| SCHEMBL5015191 | 0.82 | CA2 (0.38) | CA2CA1CA5ACA9TERT | |
| SCHEMBL25118403 | 0.75 | KDM4E (0.35) | CA2CA1CA5ACA9KCNK2 | |
| SCHEMBL1260200 | 0.74 | CYP2A6 (0.38) | CA2CA1CA5ACA9TERT | |
| SCHEMBL1230237 | 0.74 | CYP2A6 (0.38) | CA2CA1CA5ACA9TERT | |
| SCHEMBL13807591 | 0.73 | MEN1 (0.30) | ALDH1A1 | |
| SCHEMBL13036718 | 0.71 | TERT (0.35) | CA2CA1CA5ACA9TERT | |
| SCHEMBL16317228 | 0.70 | KCNK2 (0.35) | CA2CA1CA5ACA9TERT | |
| SCHEMBL28535824 | 0.69 | ALDH1A1 (0.40) | CA2CA1CA5ACA9KCNK2 | |
| SCHEMBL381447 | 0.69 | ALDH1A1 (0.58) | CA2CA1CA5ACA9KCNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829603-B2 | Stable trifluorostyrene containing compounds grafted to base polymers, and their use as polymer electrolyte membranes | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829603-B2 | Stable trifluorostyrene containing compounds grafted to base polymers, and their use as polymer electrolyte membranes | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080032184-A1 | Stable Trifluorostyrene Containing Compounds, And Their Use In Polymer Electroyte Membranes | U.S. DEPARTMENT OF ENERGY | 2008-02-07 | — | — | US | disclosed |
| US-20080032184-A1 | Stable Trifluorostyrene Containing Compounds, And Their Use In Polymer Electroyte Membranes | U.S. DEPARTMENT OF ENERGY | 2008-02-07 | — | — | US | disclosed |
| US-20070208092-A1 | Stable Trifluorostyrene Containing Compounds Grafted To Base Polymers, And Their Use As Polymer Electrolyte Membranes | U.S. DEPARTMENT OF ENERGY | 2007-09-06 | — | — | US | disclosed |
| US-20070208092-A1 | Stable Trifluorostyrene Containing Compounds Grafted To Base Polymers, And Their Use As Polymer Electrolyte Membranes | U.S. DEPARTMENT OF ENERGY | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032184-A1 | Stable Trifluorostyrene Containing Compounds, And Their Use In Polymer Electroyte Membranes | NHERF1, AFF1, SLCO2A1 | CA2 510/4885CA1 1245/4885CA5A 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.